Drug profile · INN
sepiapterin
SEPHIENCE
sepiapterin (SEPHIENCE) is an FDA-listed pharmaceutical active ingredient. Associated with PTC THERAPEUTICS, INC.. Route of administration: oral. Current US regulatory status: approved.
Drug details — sepiapterin
- US status
- approved
- Class
- Alimentary tract and metabolism (A16)
- Route
- ORAL
- Patents
- 20
- Programs
- 2
- Data quality
- 0.89
Quick answer
sepiapterin (SEPHIENCE) is an FDA-listed pharmaceutical active ingredient. Associated with PTC THERAPEUTICS, INC.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12384789
Compounds for treating Huntington's disease
granted -
US 12281083
2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof
granted -
US 12139499
Heteroaryl compounds for treating Huntington's disease
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12023335
Method for treating pancreatic cancer
granted -
US 11938101
Polymorphic forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
granted -
US 11858941
Heterocyclic and heteroaryl compounds for treating Huntington's disease
granted -
US 11786486
Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione
granted -
US 11780839
Compounds for treating Huntington's disease
granted -
US 11753407
Compounds for treating spinal muscular atrophy
granted -
US 11746077
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
granted -
US 11702646
Methods for modulating RNA splicing
granted -
US 11685746
Heteroaryl compounds for treating Huntington's disease
granted -
US 11667596
2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
granted -
US 11638706
Methods for treating Huntington's disease
granted -
US 11613538
Method of inhibiting or reducing a viral infection
granted -
US 11608501
Methods for modifying RNA splicing
granted -
US 11602567
Methods for modulating RNA splicing
granted -
US 11407753
Compounds for treating Huntington's disease
granted -
US 11395822
Methods for treating Huntington's disease
granted
Frequently asked questions
What is sepiapterin?
sepiapterin (SEPHIENCE) is an FDA-listed pharmaceutical active ingredient. Associated with PTC THERAPEUTICS, INC.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for sepiapterin?
SEPHIENCE is a marketed brand name for sepiapterin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of sepiapterin?
sepiapterin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.